This one-day workshop will bring together 100+ senior executives, CMC leaders, regulatory authorities, and market access experts in Paris to define industrial readiness for platform genetic medicines. Sessions will address control strategies and comparability, advanced analytics and genome integrity, scalable manufacturing across modalities, EMA perspectives on platform frameworks, the EU Biotech Act and speed to market, and how technical maturity drives capital formation. Designed for decision-makers shaping the future of advanced therapies, the program combines expert presentations, executive panel discussions, and a rooftop networking reception that enables meaningful engagement. You can also participate virtually.